Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials.

Published in: Clinical and experimental medicine (2022)

Therapeutic-dose anticoagulation in noncritically ill patients with Covid-19 could be indicated for patients at high risk of venous thromboembolic disease and low risk of bleeding.

Keyphrases

venous thromboembolism
atrial fibrillation
direct oral anticoagulants
coronavirus disease
sars cov
systematic review
high intensity
respiratory syndrome coronavirus